<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":4780,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
Bayer Schering Pharma AG v. Lupin, Ltd., 676 F.3d 1316, 102 U.S.P.Q.2d 1583 (Fed. Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document '>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/55b1904f2846408357ee26266414a254'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/55b1904f2846408357ee26266414a254'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation positive" title="Positive"></div>
<div class='title left' title='Bayer Schering Pharma AG v. Lupin, Ltd., 676 F.3d 1316, 102 U.S.P.Q.2d 1583 (Fed. Cir. 2012), Court Opinion'>
Bayer Schering Pharma AG v. Lupin, Ltd., 676 F.3d 1316, 102 U.S.P.Q.2d 1583 (Fed. Cir. 2012),...
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>Bayer Schering Pharma AG v. Lupin, Ltd., 676 F.3d 1316, 102 U.S.P.Q.2d 1583 (Fed. Cir. 2012), Court Opinion</div>
<div class='docId'>X1HF6KA003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>Bayer Schering Pharma AG v. Lupin, Ltd.</div>
<div class='displayCitation'>102 U.S.P.Q.2d 1583</div>
<div class='displayCitation'>2012 BL 92046</div>
<div class='displayCitation'>676 F.3d 1316</div>
<div class='displayCitation'>bna a0d1m7n4x4</div>
<div class='displayCitation'>bna a0d1q9k5c3</div>
<div class='displayCitation'>wkffecase:25939269</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1HF6KA003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="Bayer Schering Pharma AG v. Lupin, Ltd., 676 F.3d 1316, 102 U.S.P.Q.2d 1583 (Fed. Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="Bayer Schering Pharma AG v. Lupin, Ltd." />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/55b1904f2846408357ee26266414a254/document/X1HF6KA003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1HF6KA003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1HF6KA003" /><input id="title" name="title" type="hidden" value="Bayer Schering Pharma AG v. Lupin, Ltd., 676 F.3d 1316, 102 U.S.P.Q.2d 1583 (Fed. Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="POSITIVE" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="55b1904f2846408357ee26266414a254" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1HF6KA003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="true" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2F%35%35b%31%39%30%34f%32%38%34%36%34%30%38%33%35%37ee%32%36%32%36%36%34%31%34a%32%35%34%2Fdocument%2FX%31HF%36KA%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/55b1904f2846408357ee26266414a254/bcite/X1HF6KA003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/55b1904f2846408357ee26266414a254/bcite/X1HF6KA003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/55b1904f2846408357ee26266414a254/bcite/X1HF6KA003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/55b1904f2846408357ee26266414a254/related_content/X1HF6KA003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=false;
  //]]>
</script>

<!-- %table.markupContainment -->
<!-- %tbody -->
<!-- %tr -->
<!-- %td#markup_holder{:valign=>"top", :align=>"left"} -->
<div class='docHolder legal hasSearchTerms ' id='doc_holder'>
<div class='documentContent ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1699955933187";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,ReporterOfDecisions,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">676 F.3d 1316</div>
<div class="cite" data-cite-type="ReporterOfDecisions">102 U.S.P.Q.2d 1583</div>
<div class="cite" data-cite-type="DocketNumber">Nos. 2011-1143, 2011-1228.</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 92046</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">U.S.P.Q.2d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">***</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, Federal Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
BAYER SCHERING PHARMA AG and Bayer Healthcare Pharmaceuticals, Inc.,
Plaintiffs-Appellants, v. LUPIN, LTD., and Lupin Pharmaceuticals, Inc.,
Defendants-Appellees. Bayer Schering Pharma AG and Bayer Healthcare
Pharmaceuticals, Inc., Plaintiffs-Appellants, v. Sandoz, Inc.,
Defendant-Appellee, and Watson Pharmaceuticals, Inc., and Watson
Laboratories, Inc., Defendants-Appellees.
</center></p>
<hr align="center" width="65%">
<p><center>
Nos. 2011-1143, 2011-1228.
</center></p>
<p><center>
April 16, 2012.
</center></p>
<div class="headnotesToggle clearfix"><button id="toggle_headnotes_button" class="bootstrap skinButton sourceButton wide right hideSource" data-target="#headnotes_container"><span>Hide Headnotes</span></button></div>
<div class="headnotesContainer" id="headnotes_container">
<div class="headnotesContainerTitle">BNA Headnotes</div>
<div class="headnoteTitle"><a href="http://www.bloomberglaw.com/document/1475619602000128">U.S. Patents Quarterly</a></div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">PATENTS</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_914064" href="#headnote_ref_pq2-dec_914064">[1]</a> <span>Infringement &mdash; Defenses &mdash; In general </span> <a href="http://www.bloomberglaw.com/document/1699955933187/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=120.1101" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="120.1101">&#9658;120.1101</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_1" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_1" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Infringement &mdash; Inducement </span> <a href="http://www.bloomberglaw.com/document/1699955933187/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=120.15" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="120.15">&#9658;120.15</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_2" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_2" class="headnoteContent"></div>
<div class="headnote_text">
Patent infringement defendants are not liable for induced infringement under 35 U.S.C. &sect;271(b), based on their filing of abbreviated new drug applications seeking U.S. Food and Drug Administration approval to market generic versions of drug that is subject of plaintiff's patent for method of using drug to simultaneously achieve anti-androgenic, anti-aldosterone, and contraceptive effects, since patent can be infringed under 35 U.S.C. &sect;271(e)(2)(A) only if FDA approved use of drug to obtain all three effects simultaneously, but drug label's &ldquo;Indications and Usage&rdquo; section, as well as FDA's approval letter to patentee, state that drug is indicated for use as oral contraceptive, and since label, considered in its entirety, does not recommend or suggest that drug is safe and effective for inducing claimed combination of effects in patients in need thereof.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_914065" href="#headnote_ref_pq2-dec_914065">[2]</a> <span>Infringement &mdash; Defenses &mdash; In general </span> <a href="http://www.bloomberglaw.com/document/1699955933187/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=120.1101" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="120.1101">&#9658;120.1101</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_3" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_3" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Infringement &mdash; Inducement </span> <a href="http://www.bloomberglaw.com/document/1699955933187/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=120.15" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="120.15">&#9658;120.15</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_4" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_4" class="headnoteContent"></div>
<div class="headnote_text">
U.S. Food and Drug Administration regulation addressing listing of patents in &ldquo;Orange Book,&rdquo; 21 C.F.R. &sect; 314.53, which requires submission of patents that claim &ldquo;other conditions of use,&rdquo; as well as those that claim &ldquo;indications,&rdquo; does not support patentee's contention that FDA approved pharmacological anti-androgenic and anti-mineralocorticoid effects listed in &ldquo;Clinical Pharmacology&rdquo; section of label for FDA-approved oral contraceptive that is subject of plaintiff's method patent, since patentee must submit patents for listing in Orange Book &ldquo;with respect to which a claim of patent infringement could reasonably be asserted,&rdquo; 21 U.S.C. &sect; 355(b)(1), but FDA does not determine whether particular patents should be listed, and instead simply lists patents submitted by patent holders, and since category of claims for which infringement could reasonably be asserted is plainly broader than category of claims that are infringed, and new drug approval applicants need not make extrajudicial determination of actual infringement; 35 U.S.C. &sect; 271(e)(2)(A) defines filing of abbreviated new drug application but does not alter patent infringement analysis, which, for method-of-use patent, requires that accused infringer use patented product for use claimed in patent. </div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_914066" href="#headnote_ref_pq2-dec_914066">[3]</a> <span>Infringement &mdash; Defenses &mdash; In general </span> <a href="http://www.bloomberglaw.com/document/1699955933187/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=120.1101" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="120.1101">&#9658;120.1101</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_5" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_5" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Infringement &mdash; Inducement </span> <a href="http://www.bloomberglaw.com/document/1699955933187/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=120.15" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="120.15">&#9658;120.15</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_6" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_6" class="headnoteContent"></div>
<div class="headnoteSlug">JUDICIAL PRACTICE AND PROCEDURE</div>
<div class="headnoteDescriptor">
<span>Procedure &mdash; Evidence &mdash; Expert testimony </span> <a href="http://www.bloomberglaw.com/document/1699955933187/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=410.3703" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="410.3703">&#9658;410.3703</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_7" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_7" class="headnoteContent"></div>
<div class="headnote_text">
Declaration of obstetrician-gynecologist with experience in clinical use of contraceptives, stating that prescribing patented drug as oral contraceptive with intent to produce anti-mineralocorticoid and anti-androgenic pharmacological effects claimed in method patent in suit &ldquo;is clearly stated and on-label,&rdquo; is rejected as contrary to contents of FDA-approved label for drug, since label states that drospirenone is spironolactone analogue &ldquo;with antimineralocorticoid activity,&rdquo;
but does not describe extent of or summarize scientific evidence for that activity in humans, and does not provide information on safety of drug in patient needing such effect, and since label indicates only that drospirenone has been shown to generate anti-androgenic effect in preclinical studies in animals, but FDA has not determined drug to be safe or effective in inducing anti-androgenic effect in human patient, and label does not provide statement to that effect, or summarize supporting research. </div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">PATENTS</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_914067" href="#headnote_ref_pq2-dec_914067">[4]</a> <span>Infringement &mdash; Defenses &mdash; In general </span> <a href="http://www.bloomberglaw.com/document/1699955933187/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=120.1101" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="120.1101">&#9658;120.1101</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_8" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_8" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Infringement &mdash; Inducement </span> <a href="http://www.bloomberglaw.com/document/1699955933187/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=120.15" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="120.15">&#9658;120.15</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_9" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_9" class="headnoteContent"></div>
<div class="headnoteSlug">JUDICIAL PRACTICE AND PROCEDURE</div>
<div class="headnoteDescriptor">
<span>Procedure &mdash; Evidence &mdash; Expert testimony </span> <a href="http://www.bloomberglaw.com/document/1699955933187/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=410.3703" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="410.3703">&#9658;410.3703</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_10" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_10" class="headnoteContent"></div>
<div class="headnote_text">
Former U.S. Food and Drug Administration official's statement that she oversaw approval of new drug application for drug that is subject of method patent in suit, including preparation of final contents of drug's label, and that label indicates that FDA approved drug for contraception and for anti-mineralocorticoid and anti-androgenic effects claimed in patent, is rejected, since former official stated that listing pharmacological effects in &ldquo;Clinical Pharmacology&rdquo;
section of label indicated effects were confirmed and pertinent to human use of drug, but that does not mean drug is safe or effective for use in inducing those effects in patient with specific need for them. </div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">PATENTS</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_914068" href="#headnote_ref_pq2-dec_914068">[5]</a> <span>Infringement &mdash; Defenses &mdash; In general </span> <a href="http://www.bloomberglaw.com/document/1699955933187/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=120.1101" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="120.1101">&#9658;120.1101</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_11" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_11" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Infringement &mdash; Inducement </span> <a href="http://www.bloomberglaw.com/document/1699955933187/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=120.15" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="120.15">&#9658;120.15</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_12" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_12" class="headnoteContent"></div>
<div class="headnote_text">
U.S. Food and Drug Administration did not approve anti-mineralocorticoid and anti-androgenic effects of patented oral contraceptive that is subject of method patent in suit by approving certain promotional materials highlighting anti-mineralocorticoid and anti-androgenic properties of drug, since description of those effects is, in almost all cases, qualified, and FDA regulations require disclosure of specific side effects in approved labeling, and since fact that patentee framed required disclosure in positive light without crossing line into promoting such use does not mean FDA approved use not otherwise indicated in approved label. </div>
</div>
</div>
<script type="text/javascript">
					jQuery(function($) {
						$('#toggle_headnotes_button').click(document_toggleHeadnoteVisibility);
					});
				</script><div id="para2" printdualcolumn="true"><p>
  Appeal from the United States District Court for the
Southern District of New York, Paul G. Gardephe, J.
<span CLASS="page_no" data-cite="102 uspq 2d 1584" data-cite-type="ReporterOfDecisions" data-cite-pageno="1584" data-primary-citation="102 U.S.P.Q.2d 1583">[**1584]</span> </p></div>
<span CLASS="page_no" data-cite="676 f 3d 1317" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1317" data-primary-citation="676 F.3d 1316">[*1317]</span> <div id="para2" printdualcolumn="true"><p>
  Peter B. Bensinger, Jr., Bartlit, Beck Herman Palenchar
&amp; Scott, LLP, of Chicago, IL, argued for
plaintiffs-appellants. With him on the brief were Adam K.
Mortara, Paul J. Skiermont, Sundeep K. Addy and Matthew R.
Ford. Of counsel on the brief was Lawrence D. Rosenberg, Jones
Day, of Washington, DC.
<span CLASS="page_no" data-cite="102 uspq 2d 1585" data-cite-type="ReporterOfDecisions" data-cite-pageno="1585" data-primary-citation="102 U.S.P.Q.2d 1583">[**1585]</span> </p></div>
<div id="para2" printdualcolumn="true"><p>
  Mark T. Jansen, Kilpatrick Townsend and Stockton, LLP, of San
Francisco, CA, argued for all defendants-appellees. With him on
the brief were Gia L. Cincone; and Cedric C.Y. Tan and Kristin
M. Cooklin, of Washington, DC, for defendant-appellees Watson
Pharmaceuticals, Inc., et al. Also on the brief were Joseph A.
Hynds and Steven Lieberman, Rothwell, Figg, Ernst
&amp; Manbeck, P.C., of Washington, DC, for defendant-appellee Sandoz
Inc.; and Robert F. Green and Christopher T. Griffith, Leydig,
Voit &amp; Mayer, Ltd., of Chicago, IL, and Jamaica P. Szeliga,
of Washington, DC, for defendants-appellees Lupin Ltd., et al.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Christopher N. Sipes, Covington &amp; Burling LLP, of
Washington, DC, for amicus curiae Pharmaceutical Research and
Manufacturers of America. With him on the brief were Erika F.
Lietzan and Roger A. Ford.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Before NEWMAN, PLAGER, and BRYSON, Circuit Judges.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Opinion for the court filed by Circuit Judge BRYSON.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Dissenting opinion filed by Circuit Judge NEWMAN.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  BRYSON, Circuit Judge.
</p></div>
<div id="contentOpinion" printdualcolumn="true">
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Bayer Schering Pharma AG and Bayer HealthCare
Pharmaceuticals, Inc., (collectively, "Bayer") appeal from two
judgments of the United States District Court for the Southern
District of New York. In the first case, the court dismissed
Bayer's patent infringement claims against Watson
Pharmaceuticals, Inc., and Watson Laboratories, Inc.,
(collectively, "Watson") and Sandoz, Inc. In the second case,
the court dismissed similar patent infringement claims against
Lupin Ltd. and Lupin Pharmaceuticals, Inc., (collectively,
"Lupin"). We affirm.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                    I
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Drug Price Competition and Patent Term Restoration Act of
1984 ("the Hatch-Waxman Act"), Pub.L. No. <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=USACTS%2098-417&amp;summary=yes#jcite">98-417</a>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=98%20stat%201585&amp;summary=yes#jcite">98 Stat. 1585</a>, creates a procedure by which a drug manufacturer can
obtain permission from the Food and Drug Administration
<span CLASS="page_no" data-cite="676 f 3d 1318" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1318" data-primary-citation="676 F.3d 1316">[*1318]</span> 
("FDA") to market a generic version of a previously
approved drug. A manufacturer seeking to market a generic drug
is entitled to submit an Abbreviated New Drug Application
("ANDA"), rather than submitting a full New Drug Application
("NDA"). <i>Eli Lilly &amp; Co. v. Teva Pharm. USA, Inc.</i>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1AKBI8003?jcsearch=557%20f%203d%201346&amp;summary=yes#jcite">557 F.3d 1346</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1AKBI8003?jcsearch=557%20f%203d%201346&amp;summary=yes#jcite">1348</a> (Fed. Cir. 2009). The ANDA process
streamlines FDA approval by allowing the generic manufacturer
to rely on the safety and efficacy studies of a drug that has
previously been approved upon a showing that the generic
version and the <span CLASS="page_no" data-cite="2012 bl 92046 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[***2]</span> relevant listed drug share the same active
ingredients and are bioequivalent. <i>Caraco Pharm. Labs.,</i>
<i>Ltd. v. Forest Labs., Inc.</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X18N7CE003?jcsearch=527%20f%203d%201278&amp;summary=yes#jcite">527 F.3d 1278</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X18N7CE003?jcsearch=527%20f%203d%201278&amp;summary=yes#jcite">1282</a>
(Fed. Cir. 2008).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In the case of drugs that enjoy patent protection, the
Hatch-Waxman Act creates a mechanism that allows for prompt
judicial determination of whether the ANDA applicant's drug or
method of using the drug infringes a valid patent. The Act
makes it an act of infringement to file an ANDA for a drug or
for a use of the drug that is claimed in a patent.
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)(A)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(2)(A). That "artificial" act of infringement
creates jurisdiction for a court to entertain an action by the
patentee against the ANDA applicant in which issues of patent
infringement and validity can be resolved. <i>Warner-Lambert</i>
<i>Co. v. Apotex Corp.</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X17O53QNB5G0?jcsearch=316%20f%203d%201348&amp;summary=yes#jcite">316 F.3d 1348</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X17O53QNB5G0?jcsearch=316%20f%203d%201348&amp;summary=yes#jcite">1365</a> (Fed. Cir. 2003).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Hatch-Waxman Act requires an NDA applicant seeking FDA
approval for a drug that enjoys patent protection to identify
every patent that claims the drug or a use of the drug that
could reasonably be asserted in an infringement action.
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(b)(1)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(b)(1). The FDA lists the patents identified by
the NDA applicant in a publication entitled Approved Drug
Products With Therapeutic Equivalence Evaluations, which is
universally referred to in the industry as the "Orange Book."
In the case of patents claiming methods of use, FDA regulations
provide that only patents claiming "indications or other
conditions of use" that either have been approved by the FDA or
are in a pending NDA are to be submitted for listing in the
Orange Book. <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XMJ52O003?jcsearch=21%20C.F.R.%20%20314.53(b)&amp;summary=yes#jcite">21 C.F.R. &sect; 314.53</a>(b).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  When an applicant files an ANDA seeking FDA permission to
market a generic drug, it is required to address each patent in
the Orange Book that relates to that drug. <i>Eli Lilly</i>
<i>&amp; Co.</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1AKBI8003?jcsearch=557%20f%203d%201346&amp;summary=yes#jcite">557 F.3d at 1348</a>. For method-of-use patents that will
not expire prior to the proposed marketing of the generic drug,
the ANDA applicant has two options.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  First, the ANDA applicant can include a statement, known as a
"section viii statement," that the applicant is not seeking
approval for the method of use that is claimed in the patent.
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(2)(A)(viii)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)(2)(A)(viii). When submitting a
section viii statement, the ANDA applicant must include a proposed
label that removes or "carves out" the claimed method of use.
<i>See AstraZeneca LP v. Apotex, Inc.<span CLASS="page_no" data-cite="102 uspq 2d 1586" data-cite-type="ReporterOfDecisions" data-cite-pageno="1586" data-primary-citation="102 U.S.P.Q.2d 1583">[**1586]</span> </i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1EF8NE003?jcsearch=633%20f%203d%201042&amp;summary=yes#jcite">633 F.3d 1042</a>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1EF8NE003?jcsearch=633%20f%203d%201042&amp;summary=yes#jcite">1046</a> (Fed. Cir. 2010). The FDA will approve an ANDA with a
section viii statement only if (1) there is no overlap between
the proposed label submitted by the ANDA applicant and the use
described in the Orange Book, and (2) removing the information
about the claimed method of use from the label does not render
the drug less safe or effective. See
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XMJ54U003?jcsearch=21%20C.F.R.%20%20314.127(a)(7)&amp;summary=yes#jcite">21 C.F.R. &sect; 314.127</a>(a)(7); <i>see also</i> Applications for FDA Approval
to Market a New Drug, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=68%20federal%20register%2036676&amp;summary=yes#jcite">68 Fed. Reg. 36,676</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X8ICD2IO000200041GD?jcsearch=36,682&amp;summary=yes#jcite">36,682</a> (June 18,
2003) ("A section viii statement would not be appropriate
[when] the ANDA applicant is seeking approval for exactly the
same labeling as that in the NDA for which the patent was
submitted.").
<span CLASS="page_no" data-cite="676 f 3d 1319" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1319" data-primary-citation="676 F.3d 1316">[*1319]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Second, the ANDA applicant can file a "paragraph IV
certification," which states that the patent "is invalid or
will not be infringed by the manufacture, use, or sale" of the
generic drug. <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(2)(A)(vii)(IV)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)(2)(A)(vii)(IV); <i>see</i>
<i>Novo Nordisk A/S v. Caraco Pharmaceutical Laboratories,</i>
<i>Ltd.</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=601%20f%203d%201359&amp;summary=yes#jcite">601 F.3d 1359</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=601%20f%203d%201359&amp;summary=yes#jcite">1361</a> (Fed. Cir. 2010). If the ANDA
applicant files a paragraph IV certification, it must also send
<span CLASS="page_no" data-cite="2012 bl 92046 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[***3]</span> a notice letter so advising the holder of the original NDA and
the patent owner. <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(2)(B)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)(2)(B).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  For method-of-use patents, the "artificial" infringement claim
provided by <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)(A)&amp;summary=yes#jcite">section 271(e)(2)</a>(A) lies only against a patented
use that has been approved by the FDA. <i>Warner-Lambert</i>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X17O53QNB5G0?jcsearch=316%20f%203d%201348&amp;summary=yes#jcite">316 F.3d at 1356</a>. As this court explained in the
<i>Warner-Lambert</i> case, "because an ANDA may not seek
approval for an unapproved or off-label use of a drug under
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(2)(A)(i)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)(2)(A)(i), it necessarily follows that
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)(A)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(2)(A) does not apply to a use patent
claiming only such a use." <i><a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X17O53QNB5G0?jcsearch=316%20F.3d%201348&amp;summary=yes#jcite">Id</a>.; see also AstraZeneca Pharm.</i>
<i>LP v. Apotex Corp.</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1H4KCA003?jcsearch=669%20f%203d%201370&amp;summary=yes#jcite">669 F.3d 1370</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1H4KCA003?jcsearch=669%20f%203d%201370&amp;summary=yes#jcite">1377-78</a>
(Fed. Cir. 2012); <i>Allergan, Inc. v. Alcon Labs., Inc.</i>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X6CGLT?jcsearch=324%20f%203d%201322&amp;summary=yes#jcite">324 F.3d 1322</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X6CGLT?jcsearch=324%20f%203d%201322&amp;summary=yes#jcite">1334</a> (Fed. Cir. 2003).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   II
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Bayer produces and markets Yasmin, an oral contraceptive. In
2001, the FDA approved the new drug application for Yasmin that
was filed by Bayer's predecessor, Berlex Laboratories, Inc.
That application sought FDA approval for the use of Yasmin "for
oral contraception." The FDA approved the application, noting
that it had "concluded that adequate information has been
presented to demonstrate that the drug product is safe and
effective for use as recommended in the agreed upon enclosed
labeling text."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The defendants in the two cases before us have all filed ANDAs
with the FDA to market generic versions of Yasmin. The ANDAs,
which track the original NDA as required, seek FDA approval for
the use of the generic versions of Yasmin for oral
contraception. In their respective ANDAs, the defendants have
certified that the three patents that Bayer had listed in the
Orange Book in connection with Yasmin are either invalid or
would not be infringed by the manufacture, use, or sale of
their generic version of Yasmin. <i>See</i>
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(2)(A)(vii)(IV)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)(2)(A)(vii)(IV). In March 2008, Watson and Sandoz sent
notice letters to Bayer regarding their ANDA filings. In
response, Bayer filed a complaint against Watson and Sandoz in
April 2008, alleging infringement under <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)(A)&amp;summary=yes#jcite">section 271(e)(2)</a>(A) of
one of the three listed patents, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">U.S. Patent No. 5,569,652</a>
("the &prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652 patent</a>"). Lupin sent Bayer a notice letter in
June 2010 regarding its ANDA filing. Bayer filed a complaint
against Lupin in July 2010 alleging infringement of the same
patent.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The &prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652 patent</a> is a method-of-use patent with two
independent claims:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  1. A method of simultaneously achieving, during
  premenopause or menopause a gestagenic effect,
  antiandrogenic effect, and an antialdosterone effect
  in a female patient in need thereof comprising
  administering an amount of dihydrospirore-none to said
  female patient, wherein said amount of
  dihydrospirore-none is effective to simultaneously
  achieve a gestagenic effect, antiandrogenic effect and
  antialdosterone effect in said patient.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  11. A method of simultaneously achieving, during
  premenopause or menopause, a contraceptive effect, an
  anti-androgenic effect, and an antialdosterone effect
  in a female patient in need thereof comprising
  administering an effective amount of
  dihydrospirorenone and an effective amount of an
  estrogenic compound, wherein said effective
<span CLASS="page_no" data-cite="676 f 3d 1320" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1320" data-primary-citation="676 F.3d 1316">[*1320]</span> 
  amount of dihydrospirorenone is effective to
  simultaneously achieve a gestagenic effect,
  anti-androgenic effect, and <span CLASS="page_no" data-cite="2012 bl 92046 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[***4]</span> an anti-aldosterone effect
  in said female patient.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
Those claims recite that the claimed method achieves three
effects simultaneously: a contraceptive (or gestagenic) effect,
an anti-androgenic <span CLASS="page_no" data-cite="102 uspq 2d 1587" data-cite-type="ReporterOfDecisions" data-cite-pageno="1587" data-primary-citation="102 U.S.P.Q.2d 1583">[**1587]</span> effect (which reduces the activity of male
hormones and can be effective in treating conditions such as
hirsutism or acne), and an anti-aldosterone effect (also known
as an anti-mineralocorticoid effect, which can be effective in
reducing excess water retention in the body).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Watson and Sandoz moved for judgment of noninfringement on the
pleadings under Federal Rule of Civil Procedure <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X144L16003?jcsearch=Fed%20R%20Civ%20P%2012(c)&amp;summary=yes#jcite">12</a>(c). They
argued that their ANDAs related to the use of the generic form
of Yasmin only for oral contraception and not for the
combination of uses claimed in the &prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652 patent</a>.
Accordingly, they argued, they could not be held liable for
inducing infringement of that patent. The district court
granted their motions. The court held that because the FDA had
not given approval for the use of the drug that was claimed in
the &prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652 patent</a>, Bayer could not state a claim for patent
infringement. <i>Bayer Schera Pharma AG v. Sandoz, Inc.</i>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1E805E003?jcsearch=741%20f%20supp%202d%20541&amp;summary=yes#jcite">741 F.Supp.2d 541</a> (S.D.N.Y. 2010). The court explained that an
action for infringement of a method-of-use patent could be
brought under <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)(A)&amp;summary=yes#jcite">section 271(e)(2)</a>(A) only if the FDA had approved
the use claimed in the patent under the patent-holder's NDA.
The court noted that the FDA had approved the use of Yasmin
only for oral contraception, and not for the simultaneous
treatment of three conditions, which was the use claimed in the
&prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652 patent</a>. Because the court concluded that there was
nothing in the record to indicate that the defendants sought to
promote their generic versions of Yasmin based on the
anti-androgenic or anti-aldosterone properties claimed in the
&prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652 patent</a>, the court rejected Bayer's claim that the
defendants were liable for inducement of infringement under
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(b)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(b). The court therefore granted the motion and
entered judgment of noninfringement in favor of Watson and
Sandoz. Based on that ruling, Bayer and Lupin stipulated to,
and the court entered, final judgment in Bayer's suit against
Lupin as well. <i>Bayer Schering Pharma AG v. Lupin Ltd.</i>,
No. <cite>1:10-cv-05423</cite> (S.D.N.Y. Dec. 8, 2010). Bayer took appeals
from both judgments, and we consolidated the two cases for
appeal.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   III
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As the district court correctly noted, the issue in these cases
is a very narrow one. The following propositions are not in
dispute: First, Bayer does not enjoy patent protection for the
drug Yasmin or for the use of the drug for contraception alone.
<i>See Bayer Schering Pharma AG v. Barr Labs., Inc.</i>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1BEBCS003?jcsearch=575%20f%203d%201341&amp;summary=yes#jcite">575 F.3d 1341</a> (Fed. Cir. 2009). Second, the &prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652 patent</a> claims
a method of use consisting of simultaneously achieving an
anti-androgenic effect, an anti-aldosterone effect, and a
contraceptive effect in a premenopausal or menopausal female
patient in need of all three effects. Third, the only proposed
"indication for use" in the NDA application filed by Bayer's
predecessor was for oral contraception, and the only use set
forth in the "Indications and Usage" section of the label
attached to the FDA's approval letter was "for the prevention
<span CLASS="page_no" data-cite="2012 bl 92046 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[***5]</span> of pregnancy in women who elect to use an oral contraceptive."
Fourth, the Indications and Usage section of the defendants'
ANDAs used the same language and did not refer to the other
effects claimed in the &prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652 patent</a>. And finally, the
parties agree that under <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)(A)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(2)(A), the
&prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652 patent</a> can be infringed only if the defendants'
<span CLASS="page_no" data-cite="676 f 3d 1321" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1321" data-primary-citation="676 F.3d 1316">[*1321]</span> 
ANDAs seek FDA approval to market Yasmin for the three
simultaneous effects covered by the &prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652 patent</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In light of those uncontested propositions, Bayer's quarrel
with the district court is limited to contending that the FDA
<i>did</i> approve the use of Yasmin to obtain all three
effects simultaneously in menopausal and premenopausal patients
in need of all three effects, and that the defendants' ANDAs
seek FDA approval for the same uses. Bayer contends that its
label for Yasmin demonstrates that the FDA approved the use of
the drug for all three effects, and that the similar label to
be used by the defendants on their generic version of Yasmin
likewise covers the use of the drug to obtain all three effects
simultaneously in patients needing that combined treatment.
Therefore, according to Bayer, the defendants are liable for
inducing infringement by physicians and patients because the
label instructs the use of the generic drug to obtain the three
effects claimed in the &prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652 patent</a>. The district court
rejected Bayer's argument, and so do we.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                    A
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This court's 2003 decision in <i>Warner-Lambert Co. v. Apotex</i>
<i>Corp.</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X17O53QNB5G0?jcsearch=316%20f%203d%201348&amp;summary=yes#jcite">316 F.3d 1348</a> (Fed. Cir. 2003), sets the framework
for analyzing this case. In <i>Warner-Lambert</i>, the
patentee received approval from the FDA to market a particular
drug for use in treating epilepsy. Warner-Lambert's patent for
<span CLASS="page_no" data-cite="102 uspq 2d 1588" data-cite-type="ReporterOfDecisions" data-cite-pageno="1588" data-primary-citation="102 U.S.P.Q.2d 1583">[**1588]</span> use of the drug in treating epilepsy had expired, but
Warner-Lambert had an unexpired patent claiming the use of the
drug for treating neurodegenerative disease. That latter use of
the drug, however, had not been approved by the FDA. Apotex, a
generic manufacturer, filed an ANDA seeking approval to market
a generic form of the drug for the approved use of treating
epilepsy. Warner-Lambert sued under its unexpired patent, but
this court, held that it is "not an act of infringement [under
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)(A)&amp;summary=yes#jcite">section 271(e)(2)</a>(A)] to submit an ANDA for approval to market
a drug for a use when neither the drug nor that use is covered
by an existing patent, and the patent at issue is for a use not
approved" by the FDA. <i></i><a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X17O53QNB5G0?jcsearch=316%20F.3d%201348&amp;summary=yes#jcite">Id. at 1354-55</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A second case from this court, decided the same year, is even
more closely on point. In that case, <i>Allergan, Inc. v.</i>
<i>Alcon Laboratories, Inc.</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X6CGLT?jcsearch=324%20f%203d%201322&amp;summary=yes#jcite">324 F.3d 1322</a> (Fed. Cir. 2003),
Alcon, a generic drug manufacturer, filed an ANDA seeking
approval to market the unpatented drug brimonidine for the
FDA-approved use of reducing intraocular pressure. Allergan had
two patents that claimed other uses for which brimonidine was
effective: protection of the optic nerve and neural protection.
Those uses, however, were not approved by the FDA. This court
held that because those additional uses were not approved by
the FDA, the generic drug applicant could not be liable for
infringement under <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)(A)&amp;summary=yes#jcite">section 271(e)(2)</a>(A), even though
brimonidine necessarily had those protective <span CLASS="page_no" data-cite="2012 bl 92046 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[***6]</span> effects in
patients who took the drug for the approved purpose.
<i></i><a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X6CGLT?jcsearch=324%20F.3d%201322&amp;summary=yes#jcite">Id. at 1324</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_914064" href="#headnote_pq2-dec_914064">[1]</a> Based on <i>Warner-Lambert</i> and <i>Allergan</i>, the
defendants' conduct would constitute infringement under
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)(A)&amp;summary=yes#jcite">section 271(e)(2)</a>(A) (or inducement of infringement under
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(b)&amp;summary=yes#jcite">section 271(b)</a>) only if the defendants' ANDAs sought approval for the
use protected by the &prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652 patent</a>, i.e., for the
combination of a gestagenic effect, an anti-androgenic effect,
and an anti-aldosterone effect in patients needing that
combination of effects. Because the defendants' ANDAs are
substantively identical to Bayer's NDA, the use or uses for
which the ANDAs seek FDA approval are necessarily the same as
the uses for which the FDA has given its approval by granting
<span CLASS="page_no" data-cite="676 f 3d 1322" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1322" data-primary-citation="676 F.3d 1316">[*1322]</span> 
Bayer's NDA. The question to be answered, then, is whether
the FDA has approved the use of Yasmin to achieve the
combination of the three effects claimed in the &prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652
patent</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                    B
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The FDA-approved label for an approved drug indicates whether
the FDA has approved a particular method of use for that drug.
An NDA that seeks FDA approval for a particular use for a drug
must include "full reports of investigations" demonstrating
that the drug is safe and effective for that use,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(b)(1)(A)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(b)(1)(A), and it must include "the labeling proposed
to be used for such drug . . .," <i><a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(b)(1)(A)&amp;summary=yes#jcite">id</a>.</i>
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(b)(1)(F)&amp;summary=yes#jcite">&sect; 355(b)(1)(F)</a>. The FDA determines whether the information
submitted with the application shows that the drug is safe and
effective for the use described in the submitted label. <i>See</i>
<i><a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(d)&amp;summary=yes#jcite">id</a>.</i> <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(d)&amp;summary=yes#jcite">&sect; 355(d)</a> (FDA approval requires showing that "drug
is safe for use under the conditions prescribed, recommended,
or suggested in the proposed labeling thereof and that there is
"substantial evidence that the drug will have the effect it
purports or is represented to have under the conditions of use
prescribed, recommended, or suggested in the proposed labeling
thereof); <i>see also</i> Requirements on Content and Format
of Labeling for Human Prescription Drug and Biological
Products, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=71%20federal%20register%203922&amp;summary=yes#jcite">71 Fed. Reg. 3922</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X8UCGNRG000J00061GD?jcsearch=71%20federal%20register%203922&amp;summary=yes#jcite">3934</a> (2006) ("The centerpiece of
risk management for prescription drugs generally is the
labeling which reflects thorough FDA review of the pertinent
scientific evidence and communicates to health care
practitioners the agency's formal, authoritative conclusions
regarding the conditions under which the product can be used
safely and effectively.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The label for Yasmin that was approved by the FDA states in the
Indications and Usage section that "Yasmin is indicated for the
prevention of pregnancy in women who elect to use an oral
contraceptive." As noted, that characterization tracks the
FDA's approval letter for Yasmin, which stated that the NDA
"provides for the use of Yasmin . . . for oral contraception."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In claiming that the label recognizes FDA approval of all three
effects claimed in the &prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652 patent</a>, Bayer relies on the
"Pharmacodynamics" subsection of the "Clinical Pharmacology"
section of the label, which recites that drospirenone, one of
the two active compounds in Yasmin,
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  is a spironolactone analogue with
  anti-mineralocorticoid activity. Preclinical studies
  in <span CLASS="page_no" data-cite="102 uspq 2d 1589" data-cite-type="ReporterOfDecisions" data-cite-pageno="1589" data-primary-citation="102 U.S.P.Q.2d 1583">[**1589]</span> animals and <i>in vitro</i> have shown that
  drospirenone has no androgenic, estrogenic,
  <span CLASS="page_no" data-cite="2012 bl 92046 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[***7]</span> glucocorticoid, and antiglucocorticoid activity.
  Preclinical studies in animals have also shown that
  drospirenone has anti-androgenic activity.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  While that passage states that Yasmin exhibits
anti-mineralocorticoid activity and has the potential for
anti-androgenic activity based on animal studies, neither that
passage nor anything else on the label provides any safety or
efficacy information associated with the possible use of Yasmin
in treating patients who are in need of those effects. Thus,
while the label mentions potential anti-mineralocorticoid and
anti-androgenic activity, it does not do so in any way that
recommends or suggests to physicians that the drug is safe and
effective for administration to patients for the purposes of
inducing these effects.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The FDA labeling regulation, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XMJ48I003?jcsearch=21%20C.F.R.%20%20201.57&amp;summary=yes#jcite">21 C.F.R. &sect; 201.57</a>, makes
clear that the FDA has not approved the use of Yasmin to
produce the pharmacological effects that are listed in the
Clinical Pharmacology section of the label. The portion of the
regulation that is addressed to the Indications and Usage
section of the label requires the indications set forth in that
section to be supported by
<span CLASS="page_no" data-cite="676 f 3d 1323" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1323" data-primary-citation="676 F.3d 1316">[*1323]</span> 
"substantial evidence of effectiveness based on adequate
and well-controlled studies." <i><a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XMJ48I003?jcsearch=21%20C.F.R.%20%20201.57(c)(2)(iv)&amp;summary=yes#jcite">Id</a>.</i>
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XMJ48I003?jcsearch=21%20C.F.R.%20%20201.57(c)(2)(iv)&amp;summary=yes#jcite">&sect; 201.57(c)(2)(iv)</a>. The regulation adds that indications or uses
"must not be implied or suggested in other sections of the
labeling if not included in this section." <i><a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XMJ48I003?jcsearch=21%20C.F.R.%20%20201.57(c)(2)(iv)&amp;summary=yes#jcite">Id</a>.</i> The
reference in the Clinical Pharmacology section of the label to
the anti-mineralocorticoid and anti-androgenic activity of
drospirenone is certainly not a direct indication of an
appropriate use for Yasmin, and even if it could be considered
an "implied or suggested" indication of an appropriate use, the
regulation expressly states that such implied or suggested uses
do not constitute approved uses.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In addition, the FDA regulation requires the label to provide a
summary of the essential scientific information needed for the
safe and effective use of the drug. <i>See</i>
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XMJ48G003?jcsearch=21%20cfr%20201%2056&amp;summary=yes#jcite">21 C.F.R. &sect; 201.56</a>(a)(1). The Yasmin label does not provide
physicians with such a summary with respect to the drug's
antiandrogenic and anti-mineralocorticoid effects, which is a
further indication that the FDA did not approve the use of
Yasmin to exploit those effects in treating patients.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Bayer points out that the sections of the regulation directed
to the Indications and Usage portion of the label address only
"the portion of the labeling that can detail the diseases or
conditions the FDA has approved the drug to treat," and that
other effects "that do not treat a disease or condition . . .
will not be in the Indications section and will still be FDA
approved." However, whether other effects may be described
outside the Indications and Usage section of the FDA-approved
label does not address the issue in this case. The regulation
states that the Clinical Pharmacology section of the label must
include "a description of any biochemical or physiologic
pharmacologic effects of the drug or active metabolites related
to the drug's clinical effect in preventing, diagnosing,
mitigating, <span CLASS="page_no" data-cite="2012 bl 92046 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[***8]</span> curing, or treating disease, or those related to
adverse effects or toxicity."
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XMJ48I003?jcsearch=21%20C.F.R.%20%20201.57(c)(13)(i)(B)&amp;summary=yes#jcite">21 C.F.R. &sect; 201.57</a>(c)(13)(i)(B). That section of the label is also required
to describe the clinically significant pharmacokinetics of a
drug or its active metabolites; information related to in vitro
and animal studies is permitted to be included in that
section of the label only if the information is "essential to
understand dosing or drug interaction information presented in
other sections of the labeling." <i><a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XMJ48I003?jcsearch=21%20C.F.R.%20%20201.57(c)(13)(i)&amp;summary=yes#jcite">Id</a>.</i> <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XMJ48I003?jcsearch=21%20C.F.R.%20%20201.57(c)(13)(i)&amp;summary=yes#jcite">&sect; 201.57(c)
(13)(i)</a>. Thus, the fact that certain of the effects of a drug
are described in the Clinical Pharmacology section of the label
does not mean that the FDA has approved the use of the drug to
produce those effects; it only ensures that physicians are
aware of the full range of the drug's pharmacological effects
(especially those that might be considered adverse effects)
when prescribing the drug for a purpose set forth in the
Indications and Usage section and under the conditions
described in other parts of the label.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Bayer notes that FDA-approved methods of use do not invariably
appear in the Indications and Usage section of the label. For
example, an FDA-approved method of use relating to the dosage
or method of administration of a drug would appear not in the
Indications and Usage section, but in the "Dosage and
Administration" section of the label, But that does not help
Bayer in this case. The &prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652 patent</a> is narrowly focused
on simultaneously achieving three effects in premenopausal or
menopausal patients in need of all three effects; <span CLASS="page_no" data-cite="102 uspq 2d 1590" data-cite-type="ReporterOfDecisions" data-cite-pageno="1590" data-primary-citation="102 U.S.P.Q.2d 1583">[**1590]</span> as the
parties stipulated, the claim limitation referring to a
"patient in need thereof means a patient with a "perceived need
for" all three effects. The patent does not claim a, method of
achieving a contraceptive effect in a patient in need of
contraception in which the drug used to achieve the
contraceptive effect has two generally beneficial additional
effects. To
<span CLASS="page_no" data-cite="676 f 3d 1324" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1324" data-primary-citation="676 F.3d 1316">[*1324]</span> 
practice the method claimed in the &prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652 patent</a>, a
physician must determine that all three effects are needed by a
specific premenopausal or menopausal patient. FDA approval of
that method of use would require a showing that Yasmin was safe
and effective for simultaneously obtaining those three effects
in patients needing those effects. Acknowledgement of the
safety and efficacy of that specific method of use would be
evidenced by including it in the Indications and Usage
section of the label. Therefore, the point is not simply that the
method of use was not described in the Indications and Usage
section that shows lack of FDA approval; the point is that the
label, taken in its entirety, fails to recommend or suggest to
a physician that Yasmin is safe and effective for inducing the
claimed combination of effects in patients in need thereof.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   IV
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Bayer relies on four pieces of evidence to support its argument
that the references to anti-mineralocorticoid and
anti-androgenic activity in the Clinical Pharmacology
section of the Yasmin label indicate that the FDA has approved the use
of Yasmin to induce those effects: (1) the FDA regulation that
<span CLASS="page_no" data-cite="2012 bl 92046 p 9" data-cite-type="Bloomberg" data-cite-pageno="9" data-primary-citation="">[***9]</span> addresses the listing of patents in the Orange Book; (2) a
declaration from Dr. Lee Shulman, a physician; (3) a
declaration from Dr. Susan Allen, a former FDA official; and
(4) marketing materials for Yasmin that were approved by the
FDA. That evidence, however, demonstrates only that the FDA was
aware that Yasmin could cause the effects discussed in the
&prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652 patent</a>. It does not go to the critical question of
whether the FDA has found Yasmin to be safe and effective for
the purpose of inducing those effects in a premenopausal or
menopausal patient with a specific need for those effects.
Absent that finding of safety and efficacy, and the recognition
of such safety and efficacy on the Yasmin label, the Yasmin
label cannot instruct (and the ANDA proposed label cannot
induce infringement of) the method of use claimed in the
&prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652 patent</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                    A
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Bayer first relies on the FDA regulation that addresses the
requirement to submit patents for inclusion in the Orange Book,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XMJ52O003?jcsearch=21%20C.F.R.%20%20314.53&amp;summary=yes#jcite">21 C.F.R. &sect; 314.53</a>. Bayer argues that the regulation
supports its contention that the FDA approved the
pharmacological effects listed in the Clinical Pharmacology
section of the Yasmin label because the regulation requires the
submission not only of patents that claim "indications," but
also patents that claim "other conditions of use." <i><a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XMJ52O003?jcsearch=21%20C.F.R.%20%20314.53(b)&amp;summary=yes#jcite">Id</a>.</i>
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XMJ52O003?jcsearch=21%20C.F.R.%20%20314.53(b)&amp;summary=yes#jcite">&sect; 314.53(b)</a>. In Bayer's view, that requirement shows that
the FDA considered that infringement under <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)(A)&amp;summary=yes#jcite">section 271(e)(2)</a>(A)
could extend to the type of pharmacological effects detailed in
the Clinical Pharmacology section of the Yasmin label. Bayer
further contends that the regulation constitutes an
interpretation of <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)(A)&amp;summary=yes#jcite">section 271(e)(2)</a>(A), and that it is entitled
to deference under <i>Chevron V.S.A., Inc. v. Natural</i>
<i>Resources Defense Council, Inc.</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X5CAVA?jcsearch=467%20us%20837&amp;summary=yes#jcite">467 U.S. 837</a>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X5CAVA?jcsearch=104%20supreme%20court%202778&amp;summary=yes#jcite">104 S.Ct. 2778</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X5CAVA?jcsearch=81%20l%20ed%202d%20694&amp;summary=yes#jcite">81 L.Ed.2d 694</a> (1984).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_914065" href="#headnote_pq2-dec_914065">[2]</a> Bayer's argument reflects a misinterpretation of
section 314.53. The regulation implements the patent listing
requirements of <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(b)(1)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(b)(1), which requires a
patent holder to submit those patents for listing in the Orange
Book "with respect to which a claim of patent infringement
could reasonably be asserted. . . ." The fact that Bayer
submitted the &prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652 patent</a> for inclusion in the Orange
Book is not helpful to its case, for several reasons. First,
the FDA does not make a determination as to whether particular
patents should be listed in the Orange
<span CLASS="page_no" data-cite="676 f 3d 1325" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1325" data-primary-citation="676 F.3d 1316">[*1325]</span> 
Book; it simply lists those patents that are submitted by
patent holders. Second, the category of claims as to which
infringement could reasonably be asserted is plainly broader
than the category of claims that are infringed.
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(b)(1)&amp;summary=yes#jcite">Section 355(b)(1)</a> and its implementing regulations encourage broad
disclosure and do not require NDA applicants to make an
extrajudicial determination of actual infringement.
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)(A)&amp;summary=yes#jcite">Section 271(e)(2)</a>(A) defines the filing of an ANDA as an act of
infringement, but it does not alter the underlying patent
infringement analysis, which requires in the case of a
method-of-use patent that the accused infringer use the
patented product for the use claimed in the patent. <i>See</i>
<i>Warner-Lambert</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X17O53QNB5G0?jcsearch=316%20f%203d%201348&amp;summary=yes#jcite">316 F.3d at 1356</a>. Nothing in the
regulation provides any support for Bayer's position in this
case.
<span CLASS="page_no" data-cite="102 uspq 2d 1591" data-cite-type="ReporterOfDecisions" data-cite-pageno="1591" data-primary-citation="102 U.S.P.Q.2d 1583">[**1591]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                    B
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_914066" href="#headnote_pq2-dec_914066">[3]</a> Dr. Shulman, an <span CLASS="page_no" data-cite="2012 bl 92046 p 10" data-cite-type="Bloomberg" data-cite-pageno="10" data-primary-citation="">[***10]</span> obstetrician-gynecologist with experience in
the clinical use of contraceptives, stated in his declaration
that prescribing Yasmin as an oral contraceptive with the
intent to produce an anti-mineralocorticoid pharmacological
effect and an anti-androgenic pharmacological effect "is
clearly stated and on-label." That opinion, however, is
contrary to the contents of the FDA-approved label for Yasmin.
The language of the Clinical Pharmacology section of the label
does not indicate that the FDA has determined that the drug is
safe or effective in inducing those effects in patients with a
specific need for those effects, as claimed in the patent.
<i>See Warner-Lambert</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X17O53QNB5G0?jcsearch=316%20f%203d%201348&amp;summary=yes#jcite">316 F.3d at 1356</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As to Yasmin's anti-mineralocorticoid effect, the label simply
states that drospirenone is a spironolactone analogue "with
anti-mineralocorticoid activity." It does not describe the
extent of &mdash; or summarize the scientific evidence for
&mdash; that activity in humans. The Dosage and Administration
section of the label specifically describes the use of the
Yasmin "[t]o achieve maximum contraceptive effectiveness"; it
contains no discussion of the dosage required to achieve a
therapeutic level of anti-mineralocorticoid effect. Even if
knowing that drospirenone is a spironolactone analogue were all
the information a physician would need to induce a desired
therapeutic effect, the label contains no information regarding
the safety of the drag in a patient needing such an
effect.<a HREF="#fn100" name="fnref_fn100">[fn1]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Similarly, as to Yasmin's anti-androgenic effect, the
information in the Clinical Pharmacology section of the label
indicates only that drospirenone has been shown to generate
that activity in preclinical studies in animals. The FDA has
not found the drug to be safe or effective in inducing an
antiandrogenic effect in a human patient, and the label neither
provides a statement to that effect nor summarizes any
supporting research. Therefore, notwithstanding Dr. Shulman's
understanding to the contrary, any prescription of Yasmin to
produce either an anti-mineralocorticoid or anti-androgenic
effect has not been approved by the FDA and is therefore "off
label."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                    C
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_914067" href="#headnote_pq2-dec_914067">[4]</a> Dr. Allen, a former FDA official, stated that while she was at
the FDA she oversaw the approval of the Yasmin NDA, including
the preparation of final contents of the Yasmin label. Dr.
Allen stated that the label indicates that the FDA approved
Yasmin for a therapeutic effect (contraception)
<span CLASS="page_no" data-cite="676 f 3d 1326" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1326" data-primary-citation="676 F.3d 1316">[*1326]</span> 
and for the two additional pharmacological effects (the
anti-mineralocorticoid and anti-androgenic effects). Regarding
the pharmacological effects, Dr. Allen stated that listing
those effects in the Clinical Pharmacology section of the label
indicated that those effects were confirmed in Yasmin and are
"`pertinent' to human use of the drug." However, just because
those effects were confirmed and are "pertinent" to human use,
and therefore important for a prescribing physician to be aware
of, does not mean &mdash; as the dissent contends &mdash; that
the drug is safe or effective for use in inducing those effects
in a patient with a specific <span CLASS="page_no" data-cite="2012 bl 92046 p 11" data-cite-type="Bloomberg" data-cite-pageno="11" data-primary-citation="">[***11]</span> need for them. Moreover, Dr. Allen
distinguished between the contraceptive effect of Yasmin and
the other effects, stating that the FDA "approved" the
"therapeutic effect (contraceptive)" and the "two additional
pharmacological effects." Importantly, Dr. Allen did not say
that Yasmin was approved for achieving those two additional
effects in patients with a therapeutic need for those effects.
Therefore, Dr. Allen's view of the effect of FDA approval does
not draw into question the proposition that Yasmin was not
approved for the purpose of inducing the three simultaneous
effects recited in the &prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652 patent</a> in premenopausal and
menopausal patients.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                    D
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_914068" href="#headnote_pq2-dec_914068">[5]</a> Finally, Bayer argues that the FDA's approval of certain
promotional materials highlighting the anti-mineralocorticoid
and anti-androgenic properties of Yasmin indicates that the FDA
approved those pharmacological effects. The problem with that
argument is that the description of those effects is, in almost
all cases, qualified. In the case of the anti-mineralocorticoid
effect, the description is accompanied by a warning regarding
the potential for hyperkalemia in high-risk patients. In the
case of the anti-androgenic effect, the materials <span CLASS="page_no" data-cite="102 uspq 2d 1592" data-cite-type="ReporterOfDecisions" data-cite-pageno="1592" data-primary-citation="102 U.S.P.Q.2d 1583">[**1592]</span> note that
this effect is "seen in preclinical studies." The FDA's
regulations require such disclosure of "specific side effect[s]
. . . in [approved] labeling." 2.1 C.F.R. &sect; 202.1(e)(4).
That treatment is in contrast to the "clinically proved
benefits" of contraceptive efficacy and cycle control. The fact
that Bayer was able to frame a required disclosure in a
positive light without crossing the line into promoting such
use does not mean that the FDA has approved a use not otherwise
indicated in the approved label. <i>See</i>
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XMJ4BQ003?jcsearch=21%20cfr%20202%201&amp;summary=yes#jcite">21 C.F.R. &sect; 202.1</a>(e)(6)(i) (advertisement violates <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEI5OI003?jcsearch=21%20U.S.C.%20%20352(n)&amp;summary=yes#jcite">21 U.S.C. &sect; 352</a>(n),
among other reasons, if it "[c]ontains a representation or
suggestion, not approved or permitted for use in the labeling,
that a drug is . . . useful in a broader range of conditions").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                  * * *
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As applied to this case, <i>Warner-Lambert</i> and
<i>Allergan</i> make clear that the defendants do not
infringe Bayer's &prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652 patent</a> under <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)(A)&amp;summary=yes#jcite">section 271(e)(2)</a>(A)
and that their sale of the generic form of Yasmin would not
induce infringement of that patent. The defendants' ANDAs seek
approval to market the generic form of Yasmin solely for
contraceptive use, and there is no valid patent on the use of
the drug for that purpose alone. The FDA-approved label for
Yasmin does not indicate to physicians that the specific use
claimed in the &prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652 patent</a>, i.e., producing
contraceptive, anti-mineralocorticoid, and anti-androgenic
effects in premenopausal and menopausal women with a specific
need of all three effects, is safe and effective. Therefore, we
agree with the district court that the FDA has not approved
such use and that the defendants cannot be held liable for
infringement of the patent.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>AFFIRMED</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> The dissent questions whether we are finding fault with
the FDA procedures or the FDA-approved label. To the contrary,
the lack of information on the label regarding dosage and
administration to induce an anti-mineralocorticoid effect is
completely appropriate for a drug that has not been found safe
and effective for inducing that effect.
</p></div>
</div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  NEWMAN, Circuit Judge, dissenting.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court dismissed this complaint on the
pleadings under Fed.R.Civ.P.
<span CLASS="page_no" data-cite="676 f 3d 1327" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1327" data-primary-citation="676 F.3d 1316">[*1327]</span> 
12(c), thereby denying the patentee the opportunity to
litigate infringement of its <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">U.S. Patent No. 5,569,652</a> before
the defendants market their generic counterpart of the
Yasmin<span CLASS="page_no" data-cite="2012 bl 92046 p 12" data-cite-type="Bloomberg" data-cite-pageno="12" data-primary-citation="">[***12]</span> &reg; product. My colleagues err in endorsing this
dismissal, which is contrary not only to the Federal Rules and
judicial precedent, but also to the premises of FDA generic
drug practices and to the purposes of the Hatch-Waxman Act.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Motions for judgment on the pleadings pursuant to Rule 12(c)
are considered under the same standards applicable to
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X144L16003?jcsearch=Fed%20R%20Civ%20P%2012(b)(6)&amp;summary=yes#jcite">Rule 12(b)(6).</a> <i>King v. Am. Airlines, Inc.</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XAFMT1?jcsearch=284%20f%203d%20352&amp;summary=yes#jcite">284 F.3d 352</a>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XAFMT1?jcsearch=284%20f%203d%20352&amp;summary=yes#jcite">356</a> (2d Cir. 2002). Pleading standards are a matter of regional
circuit law. <i>See CoreBrace LLC v. Star Seismic LLC</i>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1B4MJI003?jcsearch=566%20f%203d%201069&amp;summary=yes#jcite">566 F.3d 1069</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1B4MJI003?jcsearch=566%20f%203d%201069&amp;summary=yes#jcite">1072</a> (Fed. Cir. 2009) ("The question . . . whether
a Rule 12(b)(6) motion was properly granted is a purely
procedural question not pertaining to patent law, to which this
court applies the rule of the regional . . . circuit."). Review
of the substantive patent law embodied in the pleadings is,
however, in accordance with the law of this court.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court held, on the pleadings as a matter of law,
that the generic counterpart of the Bayer product, brand name
Yasmin&reg;, does not infringe the &prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652 patent</a>. My
colleagues on this panel affirm, on the theory that some of the
claimed properties of the Yasmin&reg; product are not covered
by the FDA-approved label, in part because these properties are
stated in a different part of the label. The FDA-approved label
for Yasmin&reg; recites use as an oral contraceptive in the
section headed "Indications and Usage," and recites the
properties of anti-androgenic activity (acne control) and
anti-mineralocorticoid activity (diuretic effect) in the
"Clinical Pharmacology" section. The &prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652 patent</a> recites
these three effects in the same claim.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The court holds that the listing of some of the Yasmin&reg;
properties in the Clinical Pharmacology section of the FDA
label, instead of the Indications and Usage section, removes
the generic counterpart of the Yasmin&reg; product from the
scope of the &prime;652 claims. That ruling is in error, for
the portion of the FDA label in which a product's properties
are described is irrelevant to whether the patent is infringed
by sale or use of the product. The court also finds, albeit
incorrectly, that "the label, taken in its entirety, fails to
recommend or suggest to a physician that Yasmin is safe and
effective for inducing the claimed combination of effects in
patients in need thereof," maj. op. 1324, and holds that this
also requires non-infringement on the pleadings, as a, matter
of law. Neither the district court, nor this court, conducted a
standard infringement analysis.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The infringement question is whether sale or use of the generic
equivalent of the Yasmin&reg; product, in accordance with the
representations <span CLASS="page_no" data-cite="102 uspq 2d 1593" data-cite-type="ReporterOfDecisions" data-cite-pageno="1593" data-primary-citation="102 U.S.P.Q.2d 1583">[**1593]</span> in the ANDA with respect to FDA approval for
the generic equivalent of Yasmin&reg;, infringes the &prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652
patent</a>. FDA approval is embodied in the approved label for the
Yasmin&reg; product. The court concentrates on the inclusion of
the antiandrogenic and anti-mineralocorticoid activity in the
Pharmacodynamics section of the label instead of the
Indications and Usage section. The purpose of the
Pharmacodynamics section is to describe "[i]mportant
pharmacologic effects other than the main desired effect" of
the drug product. <i>See</i> FDA <i>Draft <span CLASS="page_no" data-cite="2012 bl 92046 p 13" data-cite-type="Bloomberg" data-cite-pageno="13" data-primary-citation="">[***13]</span> Guidance for</i>
<i>Industry: Clinical Pharmacology Section of Labeling for Human</i>
<i>Prescription Drug and Biological Products</i> &mdash;
<i>Content and Format</i>, cited at Rep. Br. 10. The court
now propounds the theory that the FDA label for Yasmin&reg; is
required to include specific dosages for the anti-androgenic
and anti-mineralocorticoid effects in the same section of the
label as "the main desired effect," in order for the patent to
be infringed. Maj. op. at 1325 ("The Dosage and
<span CLASS="page_no" data-cite="676 f 3d 1328" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1328" data-primary-citation="676 F.3d 1316">[*1328]</span> 
Administration section of the label specifically describes
the use of the Yasmin `[t]o achieve maximum contraceptive
effectiveness'; it contains no discussion of the dosage
required to achieve a therapeutic level of
anti-mineralocorticoid effect. Even if knowing that
drospirenone is a spironolac-tone analogue were all the
information a physician would need to induce a desired
therapeutic effect, the label contains no information regarding
the safety of the drug in a patient needing such an effect.").
I can't tell whether the court is holding that the FDA label is
fatally flawed, but even if the FDA were somehow remiss (I
discern no evidence thereof), this does not render ineffective
the patent directed to the combination of these three effects,
all of which are set forth in the FDA label for which the
generic producers have filed their ANDAs. The placement of
these effects in the FDA-approved label does not immunize the
identical generic counterpart from infringement.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The FDA's mission is to "protect public health by ensuring that
. . . drugs are safe and effective." <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X19765O003?jcsearch=21%20U.S.C.%20%20393&amp;summary=yes#jcite">21 U.S.C. &sect; 393</a>(b). In
<i>FDA v. Brown and Williamson Tobacco Corp.</i>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2TTSH?jcsearch=529%20us%20120&amp;summary=yes#jcite">529 U.S. 120</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2TTSH?jcsearch=120%20supreme%20court%201291&amp;summary=yes#jcite">120 S.Ct. 1291</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2TTSH?jcsearch=146%20l%20ed%202d%20121&amp;summary=yes#jcite">146 L.Ed.2d 121</a> (2000), the Court
explained that:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Viewing the FDCA [Food, Drug, and Cosmetic Act] as a
  whole, it is evident that one of the Act's core
  objectives is to ensure that any product regulated by
  the FDA is "safe" and "effective" for its intended
  use. . . . This essential purpose pervades the FDCA. . . .
  The FDCA requires premarket approval of any new
  drug, with some limited exceptions, and states that
  the FDA "shall issue an order refusing to approve the
  application" of a new drug if it is not safe and
  effective for its intended purpose.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2TTSH?jcsearch=529%20us%20120&amp;summary=yes#jcite">529 U.S. at 133-34</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2TTSH?jcsearch=120%20supreme%20court%201291&amp;summary=yes#jcite">120 S.Ct. 1291</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The panel majority is incorrect in its statement that the
safety and efficacy of the anti-androgenic and
anti-mineralocorticoid effects were never reviewed by the FDA.
Maj. op. at 1324 ("Absent that finding [by the FDA] of safety
and efficacy, and the recognition of such safety and efficacy
on the Yasmin label, the Yasmin label cannot instruct (and the
ANDA proposed label cannot induce infringement of) the method
of use claimed in the &prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652 patent</a>."). The Clinical
Pharmacology section of the Yasmin&reg; label discusses these
effects of the active ingredient drospirenone: "Drospirenone is
a spironolactone analogue with anti-mineralocorticoid activity. . . .
Preclinical studies in animals have also shown that
drospirenone has antiandrogenic activity."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The record contains, among other evidence, the expert
declaration of Dr. Allen, FDA past Director of the Division of
Reproductive and Urologic Drug Products, that these effects
were demonstrated when Yasmin&reg; was presented <span CLASS="page_no" data-cite="2012 bl 92046 p 14" data-cite-type="Bloomberg" data-cite-pageno="14" data-primary-citation="">[***14]</span> for FDA
approval. Dr. Allen states:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Each of the three effects identified in Claim 11 of
  the &prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652 Patent</a> are listed in the professional
  labeling for Yasmin&reg;. . . . The inclusion of
  statements describing these three effects in the
  FDA-approved labeling means that the FDA approved (a)
  the therapeutic effect (contraceptive) and (b) the two
  additional pharmacological effects (anti-androgenic
  and anti-mineralocorticoid) of Yasmin&reg;.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
When the FDA approved the Yasmin&reg; NDA, it "concluded that
adequate information has been presented to demonstrate that the
drug product is safe and effective for use as recommended in
the agreed upon enclosed labeling test." FDA Approval Letter
(May 11, 2001). Dr. Shulman, a leading
obstetrician-gynecologist with extensive experience in oral
contraceptive
<span CLASS="page_no" data-cite="676 f 3d 1329" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1329" data-primary-citation="676 F.3d 1316">[*1329]</span> 
research and clinical use, stated in his declaration that
prescriptions of Yasmin&reg; as an oral contraceptive with
intent to produce the two further pharmacological effects are
"on-label," and that he prescribes <span CLASS="page_no" data-cite="102 uspq 2d 1594" data-cite-type="ReporterOfDecisions" data-cite-pageno="1594" data-primary-citation="102 U.S.P.Q.2d 1583">[**1594]</span> Yasmin&reg; for these
additional pharmacological effects. Dr. Shulman stated:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The physician labeling for Yasmin&reg; contains the
  data supporting the use of Yasmin&reg; in the
  treatment method of claim 11 of the &prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652 patent</a>. . . .
  Because drospirenone has anti-mineralocorticoid
  activity as disclosed in the Clinical Pharmacology
  section, the prescription of Yasmin&reg; as an oral
  contraceptive with the intent to produce an
  anti-mineralocorticoid pharmacological effect is
  clearly stated and on-label. . . . Because
  drospirenone has anti-androgenic activity, the
  prescription of Yasmin&reg; as an oral contraceptive
  with the intent to produce an anti-androgenic
  pharmacological effect is clearly stated and on label. . . .
  I have prescribed Yasmin&reg; for premenopausal
  women in accordance with claim 11 of the &prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652
  patent</a>, continue to do so, and consider such
  prescriptions to be on-label.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
In <i>Bell Atlantic Corp. v. Twombly</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X17292G003?jcsearch=550%20us%20544&amp;summary=yes#jcite">550 U.S. 544</a>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=127%20supreme%20court%201955&amp;summary=yes#jcite">127 S.Ct. 1955</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X17292G003?jcsearch=167%20l%20ed%202d%20929&amp;summary=yes#jcite">167 L.Ed.2d 929</a> (2007), the Court cautioned that
"Rule 12(b)(6) does not countenance . . . dismissals based on a
judge's disbelief of a complaint's factual allegations."
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X17292G003?jcsearch=550%20us%20544&amp;summary=yes#jcite">550 U.S. at 556</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=127%20supreme%20court%201955&amp;summary=yes#jcite">127 S.Ct. 1955</a> (quoting <i>Neitzke v.</i>
<i>Williams</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X5CBP5?jcsearch=490%20us%20319&amp;summary=yes#jcite">490 U.S. 319</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X5CBP5?jcsearch=490%20us%20319&amp;summary=yes#jcite">327</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=109%20supreme%20court%201827&amp;summary=yes#jcite">109 S.Ct. 1827</a>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X5CBP5?jcsearch=104%20l%20ed%202d%20338&amp;summary=yes#jcite">104 L.Ed.2d 338</a> (1989)). Bayer has sufficiently alleged that an "intended
use" for Yasmin&reg;, as approved by the FDA, is the
simultaneous treatment of all three effects. The majority's
statement at n. 1 that Yasmin&reg; "has not been found safe and
effective" is contrary to the record.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  All of the defendants state in their ANDAs that their product
is identical to the Yasmin&reg; product and that the biological
effects are identical, with no carve-outs from the methods and
uses set forth on the FDA label. Contrary to representations
made on this appeal, defendant Sandoz described Yasmin&reg; to
the district court as "the only drug that combines the
properties of oral contraception, anti-mineralocorticoid
(antialdosterone), and anti-androgenic properties, which cause
exceptional control of acne and greatly reduced fluid
retention." J.A. 1212. Sandoz stated that "[n]o other product
offers this combination of therapeutic properties and
contraception." J.A. 1216.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The evidence before the district court, presented in response
to this motion, supported <span CLASS="page_no" data-cite="2012 bl 92046 p 15" data-cite-type="Bloomberg" data-cite-pageno="15" data-primary-citation="">[***15]</span> the statement in Bayer's complaint
that a "significant proportion of drospirenone and
ethinylestradiol prescriptions are written with the intent of
producing three pharmacological effects &mdash; gestagenic,
anti-aldosterone, and anti-androgenic." Even were these
threshold facts disputed &mdash; and they were not &mdash; it
is improper for a court to make contrary findings under
Rule 12(c). In considering a motion to dismiss, "the court is to
accept as true all facts alleged in the complaint." <i>Kassner</i>
<i>v. 2nd Ave. Delicatessen Inc.</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X17B4F2003?jcsearch=496%20f%203d%20229&amp;summary=yes#jcite">496 F.3d 229</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X17B4F2003?jcsearch=496%20f%203d%20229&amp;summary=yes#jcite">237</a> (2d
Cir. 2007).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  My colleagues hold that the &prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652 patent</a> cannot be
infringed, as a matter of law, unless the label specifically
authorizes physicians to prescribe Yasmin&reg; to treat acne or
as a diuretic. Maj. op. at 1325. This criterion of infringement
is as irrelevant as it is factually incorrect. Bayer states,
and the record adduced on this motion supports, that "Bayer
promoted the &prime;652 patented method because Yasmin&reg;'s
unique pharmacological profile differentiated it from other
oral contraceptives. The FDA pre-cleared advertising containing
this promotion because it is consistent with Yasmin&reg;'s
FDA-approved labeling," Rep. Br. 27. No contrary evidence is in
the
<span CLASS="page_no" data-cite="676 f 3d 1330" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1330" data-primary-citation="676 F.3d 1316">[*1330]</span> 
record. The adverse inferences drawn by the district court
and the adverse findings made by this court are inappropriate
as well as incorrect, for it is not disputed that all of the
defendants seek approval of their Yasmin&reg; counterpart on
representations of chemical and biological identity to the
approved Yasmin&reg; product.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The infringement inquiry is whether the generic counterpart,
when used in accordance with its proposed ANDA authorization,
would infringe the patent. The Hatch-Waxman Act does not alter
the inquiry into infringement. As summarized in Harman,
<i>Patents and the Federal Circuit</i> 494 n. 161 (9th ed.
2009): "The inquiry under <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">&sect; 271(e)(2)</a> is a standard
infringement test. The only difference is that the allegedly
infringing drug has not yet been marketed and therefore the
question of infringement must focus on what the ANDA applicant
will likely market if its application is approved." <i>See</i>
<i>also Warner-Lambert Co. v. Apotex Corp.</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X17O53QNB5G0?jcsearch=316%20f%203d%201348&amp;summary=yes#jcite">316 F.3d 1348</a>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X17O53QNB5G0?jcsearch=316%20f%203d%201348&amp;summary=yes#jcite">1366</a> (Fed. Cir. 2003) ("The proper inquiry under
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)(A)&amp;summary=yes#jcite">&sect; 271(e)(2)(A)</a> is whether, if a particular drug were put on the
market, it would infringe the relevant patent.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Whether a patent is infringed is a question of fact, and cannot
be resolved on pleadings by adverse inference or assumption.
Contrary to the theory of the panel majority,
<i>Warner-Lambert<span CLASS="page_no" data-cite="102 uspq 2d 1595" data-cite-type="ReporterOfDecisions" data-cite-pageno="1595" data-primary-citation="102 U.S.P.Q.2d 1583">[**1595]</span> </i> does not support this dismissal. In
<i>Warner-Lambert</i> the patented neurodegenerative use was
not the label-approved use, and was not the use for which the
ANDA was submitted. <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X17O53QNB5G0?jcsearch=316%20f%203d%201348&amp;summary=yes#jcite">316 F.3d at 1364</a> ("In the absence of any
evidence that Apotex has or will promote or encourage doctors
to infringe the neurodegenerative method patent [for the
"off-label" use], there has been raised no genuine issue of
material fact."). In contrast, for Yasmin&reg; it is not
disputed that the three properties recited in the patent claim
are coextensive with the FDA-approved label. Bayer's complaint,
and the several declarations provided in response to this
motion, show <span CLASS="page_no" data-cite="2012 bl 92046 p 16" data-cite-type="Bloomberg" data-cite-pageno="16" data-primary-citation="">[***16]</span> that the FDA so recognized, and also show that
physicians prescribe Yasmin&reg; for this combination of
effects. The court errs in ruling as a matter of law that the
FDA-approved label for Yasmin&reg; does not encompass the three
effects stated in the label and claimed in the &prime;<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X2H8OI62GGJ?jcsearch=usp%205569652&amp;summary=yes#jcite">652
patent</a>. Bayer's complaint contains well pleaded and
well-supported factual allegations, and states a plausible
claim of infringement. The complaint "state[s] a claim for
relief that is plausible on its face." <i>Twombly</i>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X17292G003?jcsearch=550%20us%20544&amp;summary=yes#jcite">550 U.S. at 570</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=127%20supreme%20court%201955&amp;summary=yes#jcite">127 S.Ct. 1955</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This appeal is from dismissal and judgment on the pleadings.
However, a plaintiffs nonconclusory factual allegations must be
taken as true at this stage. <i>See Swierkiewicz v. Sorema N.</i>
<i>A</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XAU33C?jcsearch=534%20us%20506&amp;summary=yes#jcite">534 U.S. 506</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XAU33C?jcsearch=534%20us%20506&amp;summary=yes#jcite">508</a> n. 1, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=122%20supreme%20court%20992&amp;summary=yes#jcite">122 S.Ct. 992</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XAU33C?jcsearch=152%20l%20ed%202d%201&amp;summary=yes#jcite">152 L.Ed.2d 1</a>
(2002) (on a motion to dismiss, the court "must accept as true
all of the factual allegations contained in the complaint.").
These firm premises are reinforced in <i>Ashcroft v.</i>
<i>Iqbal</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1B3QVK003?jcsearch=556%20us%20662&amp;summary=yes#jcite">556 U.S. 662</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1B3QVK003?jcsearch=129%20supreme%20court%201937&amp;summary=yes#jcite">129 S.Ct. 1937</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1B3QVK003?jcsearch=173%20l%20ed%202d%20868&amp;summary=yes#jcite">173 L.Ed.2d 868</a>
(2009). Yet the court discounts Bayer's factual allegations,
creating adverse inferences unrelated to either FDA approval or
the criteria of infringement. <i>See Allergan, Inc. v. Alcon</i>
<i>Labs., Inc.</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X6CGLT?jcsearch=324%20f%203d%201322&amp;summary=yes#jcite">324 F.3d 1322</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X6CGLT?jcsearch=324%20f%203d%201322&amp;summary=yes#jcite">1331</a> (Fed. Cir. 2003) ("a court
must employ a traditional infringement analysis, focusing on
all elements of infringement"). The court in <i>Allergan</i>
explained once again that the "only difference in the analysis
of a traditional infringement claim and a claim of infringement
under <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">section 271(e)(2)</a> is the time-frame under which the
elements of infringement are considered." <i><a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X6CGLT?jcsearch=324%20F.3d%201322&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Bayer is entitled to the opportunity to resolve patent
infringement at the Hatch-Waxman stage. Dismissal of the
complaint was contrary to the premises of the
<span CLASS="page_no" data-cite="676 f 3d 1331" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1331" data-primary-citation="676 F.3d 1316">[*1331]</span> 
Federal Rules, and contrary to the purposes of the
Hatch-Waxman Act. I respectfully dissent.
</p></div>
<!--BBLS DD 1699955933187-->

</div>
<div class='sideBar printHide clearfix '>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1HF6KA003/history">Direct History (17)</a>
</div>
<div class='sidebarItemLabel bold'>
No Negative Direct History
</div>
</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1HF6KA003/analysis">Case Analysis (4)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1HF6KA003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
4
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Judgment Affirmed</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Industries</div><div class='facetItemLabel'>Pharmaceuticals</div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1Q6LGEE85O2">11-01143 (Fed. Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Civil Procedure</div><div class='facetItemLabel'>Copyright Law</div><div class='facetItemLabel'>Patent Law</div><div class='facetItemLabel'>Trademark Law</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
<div class='clearfix'></div>
</div>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/55b1904f2846408357ee26266414a254/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "55b1904f2846408357ee26266414a254";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITYbd456a&previousPageId=&previousActivityInstanceId=ENTITY956ab9&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:44:37-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1HF6KA003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY956ab9&previousPageId=&previousActivityInstanceId=ENTITYedbde7&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:44:32-05:00';
FLUID_LAYOUT="false";
FULL_DOC_ID = 'X1HF6KA003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1HF6KA003";
$('#page_loader').show().spin();
JUDGE_IDS=["1850676","3027440"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
